Obesity research & clinical practice最新文献

{"title":"Excessive dietary fat and fructose enhance hepatic lipogenesis and impair mitochondrial dynamics to cause MASLD in C57BL/6 mice.","authors":"Flávia Maria Silva-Veiga, Carolline Santos Miranda, Daiana A Santana-Oliveira, Aline Fernandes-da-Silva, Carlos A Mandarim-de-Lacerda, Vanessa Souza-Mello","doi":"10.1016/j.orcp.2025.03.007","DOIUrl":"https://doi.org/10.1016/j.orcp.2025.03.007","url":null,"abstract":"<p><strong>Objective: </strong>Metabolic dysfunction-associated steatotic liver disease (MASLD) affects around 1/3 of the worldwide population, with rising prevalence. Surplus fat and carbohydrate intake are crucial for MASLD onset. This study aimed to elucidate the interference of excess lipids and fructose (32 % as energy each), alone or in combination, on the hepatic energy metabolism of male mice.</p><p><strong>Methods: </strong>Forty male C57BL/6 mice (3 months old) were randomly assigned to receive a control diet (C, 10 % of energy as soybean oil, n = 10), high-fat diet (HF, 32 % of energy as lard and 10 % as soybean oil, n = 10), high-fructose diet (HFRU, 32 % of energy as fructose, and 10 % as soybean oil, n = 10) or a diet rich in lipids and associated fructose (HF-HFRU, 32 % of energy as lard, 10 % as soybean oil, and 32 % of energy as fructose, n = 10) for 12 weeks.</p><p><strong>Results: </strong>The increased consumption of saturated fat or fructose, isolated or in association, caused oral glucose intolerance, increased hepatic triacylglycerol and cholesterol, and enhanced the expression of proteins related to hepatic inflammation, lipogenesis, mitochondrial dysfunction, and ER stress, resulting in a marked increase in hepatic steatosis.</p><p><strong>Conclusion: </strong>Our results showed that high consumption of diets rich in lipids and fructose contributed to the development of MASLD and revealed an intimate relationship between altered mitochondrial dynamics and ER stress. Understanding the molecular pathways that regulate the accumulation of hepatic lipids can lead to promising therapies for MASLD.</p>","PeriodicalId":19408,"journal":{"name":"Obesity research & clinical practice","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143788596","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of once-weekly subcutaneous semaglutide on abdominal visceral fat area in Japanese adults with overweight and obesity: A post hoc analysis of the STEP 6 trial.","authors":"Takashi Kadowaki, Tomoyuki Nishida, Wataru Ogawa, Maria Overvad, Kazuyuki Tobe, Toshimasa Yamauchi","doi":"10.1016/j.orcp.2025.03.003","DOIUrl":"https://doi.org/10.1016/j.orcp.2025.03.003","url":null,"abstract":"<p><strong>Objective: </strong>A post hoc analysis of a subset of participants with visceral fat area (VFA) measurements in the STEP 6 trial was conducted to examine both the correlation between VFA and clinical parameters and the effect of semaglutide on VFA in key subgroups.</p><p><strong>Methods: </strong>Participants were Japanese adults aged ≥ 20 years with obesity disease, randomized to once-weekly subcutaneous semaglutide 2.4 mg, semaglutide 1.7 mg, or placebo, plus lifestyle recommendations, for 68 weeks. Correlation between baseline VFA (and change in VFA from baseline to week 68) and clinical parameters (body weight, body mass index [BMI], waist circumference, hepatic parameters, glycated hemoglobin, blood pressure, lipids, high-sensitivity C-reactive protein, and plasminogen activator inhibitor-1 [PAI-1]) was evaluated. Percentage change in VFA between semaglutide and placebo was compared across subgroups.</p><p><strong>Results: </strong>Among 180 participants (semaglutide 2.4 mg, n = 89; semaglutide 1.7 mg, n = 46; placebo, n = 45), mean VFA was 170.0 cm² across subgroups. A positive correlation (Pearson's correlation coefficient [r] ≥0.3) was observed between baseline VFA and body weight (r = 0.415), BMI (r = 0.374), and both JASSO and WHO criterion waist circumference (r = 0.458 and r = 0.555). Correlation between changes in VFA and body weight, waist circumference, high-density and very low-density lipoprotein cholesterol, triglycerides, PAI-1, aspartate aminotransferase, and alanine transaminase were observed in ≥ 1 treatment arm. Semaglutide 2.4 mg and 1.7 mg reduced VFA compared with placebo in all subgroups.</p><p><strong>Conclusions: </strong>VFA partially correlated with clinical parameters in Japanese adults with obesity disease. Subcutaneous semaglutide was an efficacious treatment option for the reduction of VFA, regardless of clinical characteristics.</p><p><strong>Trial registry name: </strong>CT.gov TRIAL REGISTRATION IDENTIFICATION NUMBER: NCT03811574.</p>","PeriodicalId":19408,"journal":{"name":"Obesity research & clinical practice","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143795706","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of the hepatic and subcutaneous adipose tissue effects of triiodothyronine treatment in an animal model of metabolic syndrome.","authors":"Marta Borges-Canha, Ana Rita Leite, Glória Conceição, Catarina Vale, Madalena Von-Hafe, Diana Martins, Daniela Miranda-Silva, Cláudia Sousa-Mendes, Joana Chaves, Inês Mariana Lourenço, Carmen Grijota-Martínez, Soledad Bárez-López, Isabel M Miranda, Adelino Leite-Moreira, Inês Falcão-Pires, João Sérgio Neves","doi":"10.1016/j.orcp.2025.04.001","DOIUrl":"https://doi.org/10.1016/j.orcp.2025.04.001","url":null,"abstract":"<p><strong>Background and aims: </strong>Metabolic dysfunction associated steatotic liver disease (MASLD) is a metabolic liver disease and thyroid hormones (TH) may decrease liver fat and extra-hepatic fat content. We aimed to evaluate the effects of high and low dose triiodothyronine (T3) in liver and subcutaneous adipose tissue (sAT) in an animal model of Metabolic Syndrome (MS).</p><p><strong>Methods and results: </strong>Four groups were evaluated: 1) ZSF1 Lean (Lean-Ctrl, n = 8); 2) ZSF1 obese (rat model of MS with MASLD, MetS, n = 13); 3) ZSF1 obese supplemented with high-dose of T3 (MetS-hT3, n = 5); and 4) ZSF1 obese supplemented with a low-dose of T3 (MetS-lT3, n = 8). Treatment with both doses of T3 decreased body weight, liver weight and perirenal fat. High-dose T3 treatment normalized the increased expression of COL3A1 in MetS group. Histologically, lipid hepatic burden in treated groups was significantly reduced. Adipocytes and adipocytes' fibrosis areas were significantly reduced by the treatment with T3. MetS-hT3 had an increased risk of arrhythmias and sudden death.</p><p><strong>Conclusion: </strong>Treatment with T3 improves steatosis and fibrosis at the liver and sAT in animals with MS. High doses of T3 may not be safe due to the risk of cardiac events. Our results support new therapeutic strategies for MASLD focused on the modulation of TH.</p>","PeriodicalId":19408,"journal":{"name":"Obesity research & clinical practice","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143788592","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Questioning the role of food addiction in pediatric obesity: Comment on An et al. (2025).","authors":"Jônatas de Oliveira","doi":"10.1016/j.orcp.2025.03.004","DOIUrl":"https://doi.org/10.1016/j.orcp.2025.03.004","url":null,"abstract":"<p><p>The study by An et al. (2025) [1] investigated the association between food addiction (FA), obesity, and emotional and behavioral problems in Korean children and adolescents with overweight or obesity. While FA was linked to higher BMI, lower self-esteem, and increased emotional difficulties, critical methodological limitations challenge the clinical relevance of these findings. Cross-sectional designs require careful control of confounding variables, yet essential factors such as genetic predispositions, socioeconomic status, food environment, and family dynamics were not fully addressed. Additionally, behavioral traits like food neophobia, shown by Dos Anjos et al. (2021) [9] to influence unhealthy eating patterns in children, and neurodevelopmental conditions, such as ADHD and autism spectrum disorder, frequently co-occur with disordered eating behaviors and may confound FA classifications. Recent data from Nyholmer et al. (2024) [15] further highlight the overlap between restrictive eating profiles and psychiatric comorbidities, underscoring the need for comprehensive assessment. The study's lack of dietary pattern analysis, particularly concerning ultra-processed food intake, and absence of age-stratified reliability in dietary reporting limit its interpretability. Future research should integrate neurodevelopmental and psychiatric evaluations to clarify whether FA reflects a distinct clinical entity or broader emotional and behavioral dysregulation within pediatric obesity. Without this, the application of FA as an isolated construct remains questionable.</p>","PeriodicalId":19408,"journal":{"name":"Obesity research & clinical practice","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143743216","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to the letter to editor entitled \"Questioning the role of food addiction in pediatric obesity: Comment on An et al. (2025)\".","authors":"Hye-Ji An","doi":"10.1016/j.orcp.2025.03.005","DOIUrl":"https://doi.org/10.1016/j.orcp.2025.03.005","url":null,"abstract":"","PeriodicalId":19408,"journal":{"name":"Obesity research & clinical practice","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143730877","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Disproportionality analysis on semaglutide and nonarteritic anterior ischemic optic neuropathy in the FDA adverse event reporting system: An emerging pharmacovigilance signal?","authors":"Angela Procacci, Elisabetta Poluzzi, Fabrizio De Ponti, Emanuel Raschi","doi":"10.1016/j.orcp.2025.03.001","DOIUrl":"https://doi.org/10.1016/j.orcp.2025.03.001","url":null,"abstract":"<p><strong>Background and aim: </strong>On January 17th 2025, the European Medicines Agency started a review on semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy (NAION); we gained insight into this potential association by appraising post-marketing reporting.</p><p><strong>Methods: </strong>We queried the FDA Adverse Event Reporting System (up to December 2024) to retrieve cases of NAION reported with GLP-1 receptor agonists. Disproportionality analysis was performed by calculating the Reporting Odds Ratio (ROR) with 95 % confidence Interval (CI). Signal of Disproportionate Reporting (SDR) was defined by a lower limit of the 95 %CI> 1. To account for potential confounding by indication and channeling bias, active-comparator restricted design and disproportionality by therapeutic area were performed by comparing semaglutide vs other antidiabetic/antiobesity drugs, including SGLT2-inhibitors.</p><p><strong>Results: </strong>96 NAION cases were retrieved (83 to semaglutide), peaking 53 in last 3 months (18 from Denmark), with a median time to onset of 186 days. An SDR emerged only for semaglutide (ROR=17.57; 95 %CI=13.93-21.90), and remained significant across comparators and therapeutic indications.</p><p><strong>Conclusions: </strong>Notwithstanding limitations, including inability to infer causality, the consistency of disproportionality against a wide range of confounders together with other observational evidence raised the hypothesis of a safety signal, especially from Denmark. The exponential reporting trend calls for urgent clarification of drug-, patient- and Country-related risk factors.</p>","PeriodicalId":19408,"journal":{"name":"Obesity research & clinical practice","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143710652","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Attention to food in adolescents with obesity: No evidence for increased attentional engagement or reduced attentional disengagement.","authors":"Nienke C Jonker, Thomas A de Lang, Caroline Braet, Peter J de Jong","doi":"10.1016/j.orcp.2025.03.002","DOIUrl":"https://doi.org/10.1016/j.orcp.2025.03.002","url":null,"abstract":"<p><strong>Objective: </strong>This study examined differences in attentional engagement and disengagement bias regarding visual food stimuli between adolescents with a healthy weight versus adolescents with obesity.</p><p><strong>Method: </strong>Participants were adolescents aged 12- 23, with obesity (n = 51, adjusted BMI [(actual BMI/Percentile 50 of BMI for age and gender) × 100]) between 143 % and 313 %, and with a healthy weight (n = 51), adjusted BMI between 75 % and 129 %. Attentional bias (AB) was indexed by the Attentional Response to Distal vs. Proximal Emotional Information (ARDPEI) task.</p><p><strong>Results: </strong>Unexpectedly, results showed moderately strong evidence that individuals with obesity did not show more attentional engagement to food cues than individuals with a healthy weight, and moderately strong evidence that individuals with obesity did not show more difficulty in disengaging from food cues than individuals with a healthy weight.</p><p><strong>Conclusions: </strong>Findings provide no evidence to support the view that in adolescents AB to food cues plays a role in obesity. One conclusion could be that AB to food cues does not play a role in obesity. Yet, future studies should examine whether this might be different for adults or when satiety is well-controlled.</p>","PeriodicalId":19408,"journal":{"name":"Obesity research & clinical practice","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143692794","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Skipping breakfast and nutrient density: Influence on obesity, blood pressure, glucose, and cholesterol in elementary school students.","authors":"Hanbit Mun, Sang Woo Oh","doi":"10.1016/j.orcp.2025.02.009","DOIUrl":"https://doi.org/10.1016/j.orcp.2025.02.009","url":null,"abstract":"<p><strong>Background: </strong>Skipping breakfast is a public health issue affecting childhood obesity worldwide. However, how skipping breakfast adversely affects metabolic health in children has not been investigated comprehensively. This study investigated the associations between breakfast skipping, obesity, and cardiometabolic risk in elementary school students and identified its association with nutritional patterns.</p><p><strong>Methods: </strong>Data on 3590 elementary school students were obtained from the Korea National Health and Nutrition Examination Survey (2013-2020). Participants self-reported weekly breakfast frequency, and dietary nutrient intake was assessed using a 24-h recall survey. The associations of breakfast frequency with obesity, cardiometabolic risk factors, and nutrient density were analyzed using a survey multivariate linear regression analysis.</p><p><strong>Results: </strong>The lowest breakfast frequency group (0-2 times/week) had a higher mean body mass index (estimated mean differences; 0.80 kg/m², 95 % confidence interval (CI) 0.30-1.31) and waist circumference (2.20 cm, 0.83-3.57) than the highest frequency group (5-7 times/week). Additionally, they had higher systolic blood pressure (1.68 mmHg, 0.12-3.24), diastolic blood pressure (2.24 mmHg, 1.09-3.39), fasting glucose (1.58 mg/dL, 0.40-2.75) than the highest breakfast group. Furthermore, this group had higher percentages of energy from fat (1.96 %, 0.90-3.02), sodium density (10.29 mg/100 kcal, 0.75-19.82) and Na/K ratio (0.25 mmol/mmol, 0.11-0.40) than the highest frequency group, despite lower caloric intake.</p><p><strong>Conclusions: </strong>Elementary school students who skipped breakfast had higher obesity and cardiometabolic risk factors. These associations might be assumed from dietary nutrient patterns characterized by higher fat and sodium density despite lower daily caloric consumption.</p>","PeriodicalId":19408,"journal":{"name":"Obesity research & clinical practice","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143586420","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Weight stigma toward pregnant patients: An experimental study of medical students.","authors":"Alicia Niemann, Lara J LaCaille, Rebecca L Emery Tavernier","doi":"10.1016/j.orcp.2025.02.008","DOIUrl":"https://doi.org/10.1016/j.orcp.2025.02.008","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the presence of implicit and explicit weight bias among a sample of medical students.</p><p><strong>Methods: </strong>Using a between-subjects experimental design, medical students (N = 100; Age_M = 25.83 ± 2.76), were randomly assigned to read a vignette about a pregnant patient with a lower body mass index (BMI; 23 kg/m²) or a higher BMI (33 kg/m²). Participants then completed questionnaires related to perceptions and liking of the patient, and explicit attitudes about people who have larger bodies (i.e., BMIs ≥ 30 kg/m²).</p><p><strong>Results: </strong>There were no significant differences between vignettes, suggesting that implicit bias against pregnant patients with higher versus lower BMIs was not identified. However, weight stigmatizing attitudes were associated with medical student BMI, such that medical students with higher BMIs expressed more positive attitudes for patients with BMIs ≥ 30 kg/m² than medical students with lower BMIs.</p><p><strong>Conclusions: </strong>These findings indicate that implicit weight bias towards pregnant patients in medical students is low, particularly among medical students with higher weight, which may represent a shift in societal attitudes towards patients with larger bodies.</p>","PeriodicalId":19408,"journal":{"name":"Obesity research & clinical practice","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143586422","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of 3 G rice on plasma glucose, insulin, and gastrointestinal hormones in patients with obesity or type 2 diabetes: A non-randomized experimental study.","authors":"Chartchai Chaichana, Pornpoj Pramyothin, Witcha Treesuwan, Preechaya Jangtawee, Ahthit Yindeengam, Saroch Kaewmanee, Apichart Vanavichit, Rungroj Krittayaphong","doi":"10.1016/j.orcp.2025.02.010","DOIUrl":"https://doi.org/10.1016/j.orcp.2025.02.010","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the effects of a novel grain variety 3 G rice compared to traditional white rice on postprandial glycemia, insulinemia, and gastrointestinal hormones in individuals with obesity and type 2 diabetes (T2D).</p><p><strong>Methods: </strong>A non-randomized experimental study was conducted with 20 participants with obesity (without diabetes) and 20 patients with T2D. Each participant consumed meals containing 50 g of carbohydrates from either 3 G rice or white rice. Plasma glucose, insulin, and gastrointestinal hormone levels were measured at baseline and intervals up to 120 min post-consumption.</p><p><strong>Results: </strong>Among participants with obesity, plasma glucose levels were significantly lower at 90 and 120 after 3 G compared to white rice (0.52 ± 0.04 vs. 2.58 ± 0.37 mmol/L, p < 0.001 at 90 min and 0.06 ± 0.02 vs. 1.47 ± 0.26 mmol/L, p = 0.003 at 120 min). In contrast, plasma insulin levels were markedly higher following 3 G rice consumption at 90-120 min (p = 0.003). Gastrointestinal hormones were significantly elevated after 3 G rice intake compared to white rice, with GLP-1 levels showing sustained increases from 60 to 120 min (p = 0.019). In T2D patients, 3 G rice consumption led to a modest reduction in plasma glucose at 120 min (5.15 ± 0.49 mmol/L for white rice vs. 3.57 ± 0.35 mmol/L for 3 G rice, p = 0.0262) without significant effect on other parameters.</p><p><strong>Conclusion: </strong>3 G rice significantly improved postprandial glycemic control and enhanced gastrointestinal hormone responses in individuals with obesity. These findings highlight the promise of 3 G rice as a dietary intervention for managing postprandial glycemia and insulin sensitivity.</p>","PeriodicalId":19408,"journal":{"name":"Obesity research & clinical practice","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143557504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}